Feb. 16 at 9:41 PM
Anyone who is bullish on
$MYO, can you please discuss your bullish view? There are now several private competitors who are better positioned and make effectively better,less cumbersome, therapeutic products for stroke patients that are rapidly being adopted by clinicians and patients. Vivistim, comes to mind. Yes, it's "invasive" but its minimally invasive, only an outpatient procedure. It's also cheaper and has much stronger scientific evidence. Why would a payer or individual pay more money for a Myopro that requires finagling on a clunky device that they can't wear over clothes, adds 4-5lbs to their paretic arm, and is minimally helpful at best? Knowing there are competitors quickly stealing the serviceable obtainable market (SOM; companies always drastically overstates their market using TAM rather than SOM), why are you still bullish?
$MYO looks like a value trap. I see a fading patient pipeline and revenue that will be hard to grow again. Interested in the bullish thesis...
